Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
OsteoporeASX:OSX +12.50% Cash-to-Debt is 0.24 as of Dec. 2025, which is 96% below its 10-year median of 6.52. The stock has 7 warning signs investors should review. Among 847 Medical Devices & Instruments companies, Osteopore ranks worse than 81.94% on this metric.
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Osteopore's cash to debt ratio for the quarter that ended in Dec. 2025 was 0.24.
If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, Osteoporecouldn't pay off its debt using the cash in hand for the quarter that ended in Dec. 2025.
The historical rank and industry rank for Osteopore's Cash-to-Debt or its related term are showing as below:
ASX:OSX'
s Cash-to-Debt Range Over the Past 10 Years
Min: 0.24 Med: 6.52 Max: 47.97
Current: 0.24
During the past 8 years, Osteopore's highest Cash to Debt Ratio was 47.97. The lowest was 0.24. And the median was 6.52.
ASX:OSX's Cash-to-Debt is ranked worse than 81.94% of 847
companies
in the Medical Devices & Instruments industry
Industry Median: 1.68
vs ASX:OSX: 0.24
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.
Osteopore Cash-to-Debt Related Terms
Osteopore Cash-to-Debt Historical Data
* Premium members only.
The historical data trend for Osteopore's Cash-to-Debt can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
ASX:OSX vs ISRG, BDX, MDLN: Cash-to-Debt Comparison
For the Medical Instruments & Supplies subindustry, Osteopore's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Osteopore Cash-to-Debt vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Osteopore's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where Osteopore's Cash-to-Debt falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Osteopore (ASX:OSX) has a Cash-to-Debt of 0.24 as of Dec. 2025. This is 96% below median its historical median of 6.52. Over the past decade, Osteopore's Cash-to-Debt has ranged from 0.24 to 47.97. According to the industry distribution chart, Osteopore ranks #694 out of 847 companies in the Medical Devices & Instruments industry, placing it in the top 81.9%.
Is Osteopore's Cash-to-Debt too high?
Osteopore's current Cash-to-Debt of 0.24 is 96% below median its 10-year median of 6.52. Over the past 10 years, this metric has ranged from a low of 0.24 to a high of 47.97. The Medical Devices & Instruments industry median Cash-to-Debt is 1.68. Osteopore's value of 0.24 is 85.7% below this industry median. Based on the distribution chart, Osteopore ranks #694 out of 847 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers.
How does Osteopore's Cash-to-Debt compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Osteopore ranks #694 out of 847 companies for Cash-to-Debt. This places Osteopore in the lower half of its industry. The industry median Cash-to-Debt is 1.68. Osteopore's value of 0.24 is 85.7% below this benchmark. Historically, Osteopore's own Cash-to-Debt has ranged from 0.24 to 47.97 over the past decade. While the company's 10-year median is 6.52 vs. the industry median of 1.68, Osteopore has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash-to-Debt for a Medical Devices & Instruments company?
The median Cash-to-Debt among Medical Devices & Instruments companies is 1.68, based on 847 companies in the industry. Companies in the top quartile (top 25%) have a Cash-to-Debt significantly above this median, while those in the bottom quartile fall well below. However, Cash-to-Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Osteopore's current Cash-to-Debt of 0.24 is 85.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash-to-Debt mean?
A high Cash-to-Debt can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median Cash-to-Debt is 1.68 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Osteopore's current Cash-to-Debt is 0.24, which is 96% below median its own 10-year median of 6.52. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Osteopore stock overvalued right now?
Based on GuruFocus' analysis, Osteopore (ASX:OSX) is currently considered Possible Value Trap. The stock's GF Value™ is A$0.02, compared to a current price of A$0.00 — trading 77.5% below its estimated fair value. The current Cash-to-Debt is 0.24, which is 96% below median its 10-year median of 6.52 and 85.7% below the Medical Devices & Instruments industry median of 1.68. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash-to-Debt calculated?
Cash-to-Debt is calculated from a company's financial statements. For Osteopore (ASX:OSX), the current Cash-to-Debt is 0.24 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Osteopore Ltd is engaged in the production of 3D-printed bioresorbable implants that are used in conjunction with surgical procedures to assist bone healing. Its products include Osteoplug, which is a bioresorbable implant used for covering trephination burr holes in neurosurgery, and Osteomesh which is a bioresorbable implant used in craniofacial surgery. It operate in the high-growth regenerative medicine sector, where adoption continues to rise as healthcare systems increasingly embrace developed tissue-regenerative solutions. Business operating segments are based on the firm's geographical presence in Singapore and Australia.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:OSX has been successfully added to your 
